In comparison to GCRV-II, GCRV-III exhibited a lower level of activation in certain immune signaling pathways, while also being capable of activating pathways such as IL-17 and systemic lupus erythematosus, suggesting the induction of type II hypersensitivity reactions [43]. This evidence concerns the gene IL17A and systemic lupus erythematosus.